ClinicalTrials.gg
RecruitingNCT05287451Updated Oct 15, 2026

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

An interventional study of RIsk-Reducing Salpingectomy (RRS) and Risk-Reducing Oophorectomy-RRO in Ovarian Cancer and Fallopian Tube Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 11 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Updated Oct 15, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center — 15 open to participants now, 31 under way, 1 of them phase 3. Ovarian Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
10th of 61
100 · median 30
Started
2022
with 5 others
No phase
10 of 78
5 open now
Primary completion
2026-12
later than 2 of 30 live
Registered
68th of 78
by date

Among the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, this one is the 10th largest by planned enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2022, is one of 10 with no phase, reaches primary completion later than 2 of the 30 other live ones, and was the 68th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

15 of the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center are open now, in 5 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

Read the detailed description

The aim of the project is to evaluate RRS with delayed RRO as an alternative for RRSO in BRCA1/2 gene germline mutation carriers with respect to ovarian cancer incidence. We hypothesize that postponement of oophorectomy and consequent menopause to the age of 40-45 (BRCA1) or 45-50 (BRCA2) compared to current standard RRSO at age 35-40 (BRCA1) or 40-45 (BRCA2) will not lead to a significant increase in ovarian cancer risk.

PRIMARY OBJECTIVE:

To evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence in BRCA1/2 gene germline mutation carriers.

SECONDARY OBJECTIVE:

Incidence of (pre)malignant findings in tubes/ovaries, perioperative morbidity and mortality, incidence of non-ovarian pelvic cancer, breast cancer, prophylactic breast surgery and uptake of risk reducing oophorectomy.

EXPLORATORY OBJECTIVE:

Estimate high grade serous (ovarian) cancer incidence for innovative and standard treatments in BRIP1, RAD51C, and RAD51D gene germline mutation carriers

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  1. Premenopausal women with a documented deleterious mutation in BRCA1, BRCA2, BRIP1, RAD51C, PALB2 and/or RAD51D gene germline mutation.
  2. Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2 and 30-50 years for BRIP1, RAD51C, RAD51D, and PALB2.

    • The highest risk for cancer is mediated by the BRCA mutation. If a patient has multiple mutations, eligibility will be based on BRCA mutation.
  3. No longer requires fallopian tubes for natural childbearing. Future plans for IVF are acceptable.
  4. Presence of at least one fallopian tube.
  5. Participants may have a personal history of non-ovarian .
  6. must be obtained and documented.

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. status (natural menopause or due to (cancer) treatment)

    • A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
    • A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation per the local standard of care can be considered.
  2. Wish for second stage RRO within two years after RRS (if clear at enrollment)
  3. Legally incapable
  4. Prior bilateral salpingectomy
  5. A personal history of ovarian, fallopian tube, or peritoneal cancer
  6. Current clinicals signs, diagnosis, or treatment for malignant disease. Aromatase Inhibitors, Tamoxifen, and Selective Estrogen Receptor Modulators (SERM) are allowed.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Risk-Reducing Salpingectomy-RRS

    Can help to lower the risk of ovarian cancer with a delayed removal of 1.

    Other: RIsk-Reducing Salpingectomy (RRS)

  • Other
    Risk-Reducing Oophorectomy-RRO

    Can help to lower the risk of ovarian cancer removing both fallopian tubes.

    Other: Risk-Reducing Oophorectomy-RRO

  • Other
    Risk-Reducing Salpingo-Oophorectomy-RRSO

    Can help to lower the risk of ovarian cancer as well as the standard-of-care risk-reducing procedure involving the removal of the fallopian tubes and ovaries (risk-reducing salpingo-oophorectomy-RRSO)

    Other: Risk-Reducing Salpingo-Oophorectomy-RRSO

Interventions

  • OtherRIsk-Reducing Salpingectomy (RRS)

    complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure

  • OtherRisk-Reducing Oophorectomy-RRO

    complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure

  • OtherRisk-Reducing Salpingo-Oophorectomy-RRSO

    complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure

06

What researchers measure

Primary outcomes

  1. To evaluate the non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence in BRCA1/2 gene germline mutation carriers.

    Time frame: through study completion, an average of 15 years

07

Study locations

11 of 11 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 282 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 76. This study's planned 55 months is above that.

Counting every sponsor, half of 293 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Mar 18, 2022
StartActual
May 10, 2022
Primary completionEst.
Dec 26, 2026
CompletionEst.
Dec 26, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • University of Chicago · Chicago, United States
  • Duke University · Durham, United States
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Chicago · Chicago, United States
    • Duke University · Durham, United States
    + 1 other change: verification date
  2. Sep 29, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05287451
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
May 10, 2022
Primary completion
Dec 26, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

Roni Wilke, MD
Contact
rnitecki@mdanderson.org
(713) 822-4502
Roni Wilke, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion